Johnson & Johnson Reports Lower Mortality for Impella-Supported HRPCI Versus CHIP-BCIS3

Johnson & Johnson reported three analyses showing lower in-hospital and 30- and 90-day mortality for patients who received Impella-supported high-risk PCI in real-world U.S. and EU data compared with CHIP-BCIS3, covering 1,379 patients. TradingView carried the report on November 1, 2026.

What the Three Impella Analyses Found

Johnson & Johnson said the analyses compared Impella-supported high-risk percutaneous coronary intervention patients in real-world U.S. and EU data against CHIP-BCIS3. The company reported lower in-hospital cardiovascular mortality for the Impella-supported group. It also reported lower mortality at 30 days and at 90 days after the procedure.

The analyses covered 1,379 HRPCI patients. Johnson & Johnson noted support duration as a factor in the outcomes. The company said the PROTECT IV randomized controlled trial readout is anticipated in 2027.

Johnson & Johnson is the New Brunswick-based pharmaceutical and medical technology group led by chairman and chief executive officer Joaquin Duato, according to company records. Its MedTech segment includes the Impella heart pump line.

Johnson & Johnson's Scale Behind the Impella Program

Johnson & Johnson raised its 2026 sales guidance to a $100.8 billion midpoint after reporting 9.9% first-quarter sales growth to $24.1 billion, according to akta.pro company records. The company reported $94.2 billion in revenue for 2025 with 6% growth and net income of $26.8 billion. The same records list a $1.5 million grant in August 2026 led by the North Carolina Department of Commerce.

Earlier Johnson & Johnson Trial Results

On October 24, 2026, Johnson & Johnson announced PROTEUS substudy results showing apalutamide plus androgen deprivation therapy before and after surgery reduced the risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer, PR Newswire reported. The same day, Yahoo reported that the company said its experimental prostate cancer drug caused tumors to shrink or disappear in an early-stage trial, with PSA levels falling by at least 50% in 77% of 31 evaluable patients.

On October 29, 2026, Seeking Alpha reported that Johnson & Johnson posted third-quarter revenue of $25.4 billion, up 5.9%, and raised its 2026 adjusted EPS forecast to $11.10.

Johnson & Johnson's December 8 Review

Johnson & Johnson will host an Enterprise Business Review for the investment community on December 8, 2026, with presentations from company leaders on Innovative Medicine and MedTech, Stock Titan reported.